Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Symptomology, Outcomes and Risk Factors of Acute Coronary Syndrome Presentations without Cardiac Chest Pain: A Scoping Review
Author(s): Meriem Perona , Amanda Cooklin , Christopher Thorpe , et al Added: 1 year ago

MI/ACS
AF Symposium 26: Balloon-in-Basket PFA without Propofol
Author(s): Roland R Tilz Added: 4 months ago
AF Symposium 2026 - Prof Roland Tilz (University Heart Center Lübeck, DE) discusses an innovative awake workflow for atrial fibrillation ablation using pulsed field ablation technology with the Volt balloon-in-basket system, eliminating the need for propofol-based deep sedation.Patient experience data revealed nuanced outcomes: while intraprocedural pain scores averaged 7/10 during energy… View more

Electrophysiology & Arrhythmia
ADA 25: MariTide Treatment for Obesity in Patients with or without T2D
Author(s): Harold Bays Added: 11 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once… View more

Cardiovascular Kidney Metabolic
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 7 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
ACC.26 Late-breaker Discussion: The PRO-TAVI Trial
Author(s): Michiel Voskuil , Harriette Van Spall Added: 2 months ago
ACC.26 – Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined onsite by Michiel Voskuil (UMC Utrecht, Utrecht, NL) to discuss the PRO‑TAVI trial, a multicenter randomized study comparing TAVI with or without routine preprocedural PCI in patients with severe aortic stenosis and concomitant coronary artery disease. PRO‑TAVI tackles the ongoing controversy over… View more

Intervention
30th Annual Meeting of the ISCP
Author(s): Raúl Ludeña , Raúl Ptaszynski Lanza , Francisco González , et al Added: 2 months ago

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Andrés Álvarez , Diego Manuel de la Eranueva , Manuel Sánchez , et al Added: 2 months ago

Prevention & Chronic Conditions
Job title: Consultant Interventional Cardiologist
Dr Kalpa De Silva has been a consultant interventional cardiologist at Guy's and St Thomas'NHS Foundation Trust since 2020. Previously he was a consultant interventional cardiologist at the Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust. He specialises in the management of coronary artery disease, looking after patients with chest pain, angina and those who have… View more
Evangelos Giannitsis
Research Area(s) / Expertise:

Expertise

MI/ACS
Job title: Assistant Professor of Medicine in Heidelberg
Dr. Giannitsis, an Assistant Professor of Medicine based in Heidelberg, holds a medical degree from the University of Homburg. He pursued advanced training in internal medicine and cardiology at Lübeck University Hospital in Germany. Additionally, he completed a Ph.D. in internal medicine before assuming his current role in 2002. Dr. Giannitsis's research is centered on cardiac biomarkers,… View more
Plaque Burden on CCTA Predicts MACE in Early CAD
Added: 3 months ago Source:  Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance… View more

Imaging & Diagnostics

Prevention & Chronic Conditions